Trials / Completed
CompletedNCT04126707
The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans
A Single-center, Open-label, Single-dose Phase I Study to Investigate the Absorption, Metabolism and Excretion of [14C] HQP1351 After a Single Oral 30mg (100µCi) Dose in Healthy Chinese Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Ascentage Pharma Group Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to determine the mass balance and routes of excretion of total radioactivity after a single oral 30mg (100µCi) dose of \[14C\] HQP1351 given as a suspension. For further clinical development, human mass balance data are required to elucidate the absorption, metabolism, and excretion of HQP1351.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C] HQP1351 | Orally, single dose of 30mg |
Timeline
- Start date
- 2019-11-19
- Primary completion
- 2020-01-13
- Completion
- 2020-01-13
- First posted
- 2019-10-15
- Last updated
- 2021-09-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04126707. Inclusion in this directory is not an endorsement.